GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Directing the metabolic fate of CAR T cells

$432,308
Carl H. June · University Of Pennsylvania · R01 · FY2018 · CA

Directing the metabolic fate of CAR T cells

$432,308
Carl H. June · University Of Pennsylvania · R01 · FY2021 · CA

MULTIPLEX CHEMICAL TAGS FOR HIGH-THROUGHPUT GLYCAN AND GLYCOPEPTIDE QUANTITATION AND CHARACTERIZATION

$432,228
Lingjun Li · University Of Wisconsin-Madison · U01 · FY2020 · CA

Targeting aberrant enhancer landscapes in pancreatic cancer

$432,000
Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2024 · CA

Targeting aberrant enhancer landscapes in pancreatic cancer

$432,000
Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2025 · CA

Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma

$431,993
Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2025 · CA

Monitoring Listeria in vivo using 18FDG and PET scan

$431,970
Claudia Gravekamp · Albert Einstein College Of Medicine · R21 · FY2024 · CA

Systematic characterization of cancer variants using single-cell functional genomics

$431,914
Thomas Maxwell Norman · Sloan-Kettering Inst Can Research · R33 · FY2023 · CA

In situ protein analysis of laser dissected cell ensembles

$431,750
Alexandra Ros · Arizona State University-Tempe Campus · R21 · FY2020 · AG

Targeting pancreatic cancer's metabolic addiction to HuR

$431,688
Jordan M Winter · Case Western Reserve University · R37 · FY2023 · CA

Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis

$431,561
Linda M S Resar · Johns Hopkins University · R01 · FY2024 · CA

CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial

$431,536
Matthew T. Moyer · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2020 · CA

Development of Methods for Cancer Biomarker Detection

$431,348
Wistar Institute · R33 · FY2002 · CA

P-4: Direct Delivery of Immune-modulating Therapies to the Pancreatic Tumor Site

$431,346
Pinku Mukherjee · Mayo Clinic Rochester · P50 · FY2012 · CA

Mechanisms of diabetic amyloid formation via 2D IR spectroscopy

$431,169
Martin T Zanni · University Of Wisconsin-Madison · R01 · FY2023 · DK

Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma

$431,094
Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2021 · CA

Thrombin-dependent mechanisms of pancreatic ductal adenocarcinoma disease

$431,066
Matthew J. Flick · Cincinnati Childrens Hosp Med Ctr · R01 · FY2017 · CA

Clinical protocols for the treatment of gastrointestinal cancer

$431,019
Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Development and application of asymmetric-flow field-flow (AF4) technology in fractionation and characterization of exosome subpopulations and novel nanoveiscles in pancreatic cancer model

$430,996
David Charles Lyden · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · CA

Exosomes as Endocrine Signaling Molecules in Cancer Cachexia

$430,995
Daniel L Marks · Oregon Health & Science University · R01 · FY2022 · CA

Understanding and targeting mutant splicing factors in pancreatic cancer

$430,974
Luisa Escobar Hoyos · Yale University · R01 · FY2022 · CA

Southern California Research Center for ALPD and Cirrhosis

$430,973
Hidekazu Tsukamoto · University Of Southern California · P50 · FY2024 · AA

Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA

$430,866
New York University School Of Medicine · R01 · FY2005 · CA

Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer

$430,604
Pankaj Kumar Singh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2025 · CA

Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer

$430,604
Pankaj Kumar Singh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2022 · CA